Peter Zandstra Joins Aspect Biosystems as an Advisor

Feb 20, 2017

VANCOUVER, British Columbia – February 20, 2017 – Aspect Biosystems Ltd., a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering, is pleased to announce that Dr. Peter Zandstra will join the company as an advisor. “We are delighted to welcome Peter Zandstra to our team of advisors,” says Tamer Mohamed, President and CEO of Aspect Biosystems. “Peter is a world leader in the field of regenerative medicine and brings years of highly relevant experience to our team. As we continue to advance the application of our 3D printing technology in the field of regenerative medicine, Peter’s insight and knowledge will be valuable assets to the company.”

Peter Zandstra (PhD FRSC) is a Professor at the University of Toronto’s Institute of Biomaterials and Biomedical Engineering, with a cross appointment in the Donnelly Centre for Cellular and Biomolecular Research. Peter is also a Professor at UBC in the Departments of Medical Genetics and Chemical Engineering and Biological Engineering. He serves as the Executive Director of Medicine by Design (MbD) and as Chief Scientific Officer at CCRM, a Toronto-based regenerative medicine translation centre. Dr. Zandstra is the Canada Research Chair in Stem Cell Bioengineering and the recipient of a number of awards and fellowships. His research integrates engineering and biological approaches and in the last several years, work in his lab has focused on using computer modelling and strict control of the microenvironment (niche engineering) to develop a deeper understanding of the regulatory networks that determine stem cell fate. In addition, Dr. Zandstra co-founded three biotech companies including ExCellThera, a clinical stage cell therapy company that focuses on novel treatments for blood diseases.  

About Aspect Biosystems Ltd.

Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.

Back to all